An insight into water of crystallization during processing using vibrational spectroscopy

Journal of Pharmaceutical Sciences

Volumn 98, Issue 11, 2009, Pages 3903-3932

  Jørgensen, Anna Cecilia ^a,d   Strachan, Clare J ^b,e   Pöllänen, Kati H ^c   Koradia, Vishal ^a   Tian, Fang ^a   Rantanen, Jukka ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF HELSINKI   (Finland)

^c LAPPEENRANTA UNIVERSITY OF TECHNOLOGY   (Finland)

^d Ferrosan AS   (Denmark)

^e UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Dehydration; Hydrate formation; Hydrates; Infrared spectroscopy; Near infrared spectroscopy; Processing; Processing induced transformations; Raman spectroscopy; Spectroscopy; Terahertz spectroscopy

Indexed keywords

ORGANIC COMPOUND; WATER;

COMPRESSION; CRYSTALLIZATION; FREEZE DRYING; GRINDING; INFRARED SPECTROSCOPY; RAMAN SPECTROMETRY; REVIEW; TERAHERTZ SPECTROSCOPY;

EID: 70349651195     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21735     Document Type: Article

References (152)

1. Griesser UJ. 2006. The importance of solvates. In: Hilfiker R, editor. Polymorphism in the Pharmaceutical Industry. 1st edition. Weinheim, Germany: Wiley-VCH. pp. 211-233.
2. Grant DJW, Higuchi T. 1990. Solubility behavior of organic compounds. 1st edition. New York: John Wiley & Sons, Inc.
3. Khankari RK, Grant DJW. 1995. Pharmaceutical hydrates. Thermochim Acta 248:61-79.
4. Lohani S, Grant DJW. 2006. Thermodynamics of polymorphs. In: Hilfiker R, editor. Polymorphism in the pharmaceutical industry. 1st edition. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA. pp. 21-42.
5. Morris KR, Rodríguez-Hornedo N. 1993. Hydrates. In: Swarbrick J, Boylan JC, editors. Encyclopedia of pharmaceutical technology. 1st edition. New York: Marcel Dekker, Inc. pp. 393-440.
6. Morris KR. 1999. Structural aspects of hydrates and solvates. In: Brittain HG, editor. Polymorphism in pharmaceutical solids. New York, NY, USA: Marcel Dekker, Inc. pp. 125-181.
7. Wong MWY, Mitchell AG. 1992. Physicochemical characterization of a phase-change produced during the wet granulation of chlorpromazine hydrochloride and its effects on tabletting. Int J Pharm 88:261-273.
8. Sun CQ, Grant DJW. 2004. Improved tableting properties of p-hydroxybenzoic acid by water of crystallization: A molecular insight. Pharm Res 21:382-386.
9. Dziki W, Bauer JF, Szpylman JJ, Quick JE, Nichols BC. 2000. The use of near-infrared spectroscopy to monitor the mobility of water within the sarafloxacin crystal lattice. J Pharm Biomed Anal 22:829-848. (Pubitemid 30193314)
10. York P. 1983. Solid-state properties of powders in the formulation and processing of solid dosage forms. Int J Pharm 14:1-28. (Pubitemid 13144964)
11. Shefter E, Higuchi T. 1963. Dissolution behavior of crystalline solvated and nonsolvated forms of some pharmaceuticals. J Pharm Sci 52:781-791.
12. Li XW, Zhi F, Hu YQ. 2007. Investigation of excipient and processing on solid phase transformation and dissolution of ciprofloxacin. Int J Pharm 328:177-182. (Pubitemid 44883402)
13. Herman J, Visavarungroj N, Remon JP. 1989. Instability of drug release from anhydrous theophylline microcrystalline cellulose formulations. Int J Pharm 55:143-146. (Pubitemid 19253784)
14. Rodriguez-Hornedo N, Lechuga-Ballesteros D, Wu HJ. 1992. Phase-transition and heterogeneous epitaxial nucleation of hydrated and anhydrous theophylline crystals. Int J Pharm 85:149-162.
15. Phadnis NV, Suryanarayanan R. 1997. Polymorphism in anhydrous theophylline - Implications on the dissolution rate of theophylline tablets. J Pharm Sci 86:1256-1263. (Pubitemid 27486097)
16. Kobayashi Y, Ito S, Itai S, Yamamoto K. 2000. Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrate. Int J Pharm 193:137-146. (Pubitemid 30001856)
17. Byrn SR, Sutton PA, Tobias B, Frye J, Main P. 1988. The crystal-structure, solid-state NMR-spectra, and oxygen reactivity of 5 crystal forms of prednisolone tert-butylacetate. J Am Chem Soc 110:1609-1614. (Pubitemid 18066749)
18. Allen DJM, Busch FR, DiRoma SA, Godek DM. 1994. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dih ydro-2H-indol-2-one-hydrochloride. United States Patent 5312925.
19. Clas SD, Crocker LS, McCauley JA, Davies I, Dalton C. 2002. Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonyphenyl)-6′- methyl-[2,3′]bipyridinyl. United States Patent 5849752.
20. Dunn PJ, Matthews JG, Newbury TJ, O'Connor G. 1999. Stable hydrate of a muscarinic receptor antagonist. United States Patent 5849752.
21. Grunenberg A, Bosche P. 1998. Crystal modification of CDCH a process for its preparation and pharmaceutical formulations comprising this modification. United States Patent 5849752.
22. Hrakovsky J, Tebebgauzer R. Dry formulations of aripiprazole. United States Patent Application 2007154545.
23. Phan HV, Allen RH, Coats RA. 1999. Sodium (S)-2-(6-methoxy-2-naphthyl) propionate monohydrate. United States Patent 5874614.
24. Cazer F, Parry GE, Billings DM, Redman-Furey NL. 2002. Selective crystallization of 3-pyridyl-1-hydroxyethylidene-1, 1-bisphosphonic acid sodium as the hemipentahydrate or monohydrate. United States Patent 641520.
25. Finkelstein N, Lidor-Hadas R, Aronhime J. 2004. Hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof. United States Patent 6696601.
26. Godlewski JE. 2009. Process for controlling crystal structure of risedronate. United States Patent 7002014.
27. Zook SE, Hettinger D. 2007. Hydrate of N-methyl-N-(3-{3-[2- thienylcarbonyl]-pyrazol-[1,5.alpha.]-pyrim-idin-7-yl}phenyl)acetamide and processes and methods related thereto. United States Patent 7304069.
28. Fox M, Cohen R, Braunstein A, Leibovici M. 2008. Stable pharmaceutical formulation of paroxetine hydrochloride anhydrous and a process for preparation thereof. United States Patent 7396542.
29. Jona J, Kanapuram S, Daurio D. 2007. Wet granulation process for pharmaceuticals. United States Patent Application 20070110802.
30. Bernstein J. 2006. Polymorphism and patent from a chemist's point of view. In: Hilfiker R, editor. Polymorphism in the pharmaceutical industry. 1st edition. Weinhein, Germany: Wiley-VCH. pp. 365-384.
31. Cardew PT, Davey RJ. 1985. The kinetics of solvent-mediated phase-transformations. Proc Math Phys Eng Sci 398:415-428.
32. Davey RJ, Cardew PT, Mcewan D, Sadler DE. 1986. Rate controlling processes in solvent-mediated phase-transformations. J Cryst Growth 79:648-653.
33. Rodriguez-Hornedo N, Murphy D. 1999. Significance of controlling crystallization mechanisms and kinetics in pharmaceutical systems. J Pharm Sci 88:651-660. (Pubitemid 29325991)
34. Murphy D, Rodriguez-Cintron F, Langevin B, Kelly RC, Rodriguez-Hornedo N. 2002. Solution-mediated phase transformation of anhydrous to dihydrate carbamazepine and the effect of lattice disorder. Int J Pharm 246:121-134. (Pubitemid 35247985)
35. Sacchetti M. 2004. Determining the relative physical stability of anhydrous and hydrous crystal forms of GW2016. Int J Pharm 273:195-202. (Pubitemid 38317052)
36. Groen H, Roberts KJ. 2001. Nucleation, growth, and pseudo-polymorphic behavior of citric acid as monitored in situ by attenuated total reflection Fourier transform infrared spectroscopy. J Phys Chem B 105:10723-10730. (Pubitemid 35338563)
37. Qu HY, Louhi-Kultanen M, Rantanen J, Kallas J. 2006. Solvent-mediated phase transformation kinetics of an anhydrate/hydrate system. Cryst Growth Des 6:2053-2060. (Pubitemid 44450336)
38. Petit S, Coquerel G. 1996. Mechanism of several solid-solid transformations between dihydrated and anhydrous copper(II) 8- hydroxyquinolinates. Proposition for a unified model for the dehydration of molecular crystals. Chem Mater 8:2247-2258.
39. Galwey AK. 2000. Structure and order in thermal dehydrations of crystalline solids. Thermochim Acta 355:181-238.
40. Colthup N, Daly L, Wiberley S. 1990. Introduction to infrared and Raman spectroscopy. 3rd edition. San Diego: Academic Press, Inc.
41. Wülfert F, Kok WT, Smilde AK. 1998. Influence of temperature on vibrational spectra and consequences for the predictive ability of multivariate models. Anal Chem 70:1761-1767. (Pubitemid 128484577)
42. Harrick NJ. 1979. Internal reflection spectroscopy. 1st edition. New York: Harrick Scientific Corp.
43. Workman J, Springsteen AW. 1997. Applied spectroscopy. A compact reference for practioners. 1st edition. London: Academic Press Ltd.
44. Pöllänen K, Häkkinen A, Huhtanen M, Reinikainen SP, Karjalainen M, Rantanen J, Louhi-Kultanen M, Nyström L. 2005. FT-IR for quantitative characterization of polymorphic composition of sulfathiazole. Anal Chim Acta 544:108-117. (Pubitemid 40823046)
45. Burns DA, Ciurczak EW. 2001. Handbook of near-infrared analysis. 2nd edition. Basel, Switzerland: Marcel Dekker AG.
46. Osborne BG, Fearn T, Hindle PH. 1993. Practical NIR spectroscopy with applications in food and beverage analysis. 2 edition. Harlow, UK: Longman Group UK.
47. Curcio JA, Petty CC. 1951. The near infrared absorption spectrum of liquid water. J Opt Soc Am 41:302-304.
48. Buijs K, Choppin GR. 1963. Near-infrared studies of structure of water. 1. Pure water. J Chem Phys 39:2035-2041.
49. Choppin GR, Violante MR. 1972. Near-infrared studies of structure of water. 3. Mixed solvent systems. J Chem Phys 56:5890-5898.
50. Maeda H, Ozaki Y, Tanaka M, Hayashi N, Kojima T. 1995. Near infrared spectroscopy and chemometrics studies of temperature-dependent spectral variations of water: Relationship between spectral changes and hydrogen bonds. J Near Infrared Spectrosc 3:191-201. (Pubitemid 127108592)
51. Räsänen E, Rantanen J, Jørgensen A, Karjalainen M, Paakkari T, Yliruusi J. 2001. Novel identification of pseudopolymorphic changes of theophylline during wet granulation using near infrared spectroscopy. J Pharm Sci 90:389-396.
52. Zhou GX, Ge ZH, Dorwart J, Izzo B, Kukura J, Bicker G, Wyvratt J. 2003. Determination and differentiation of surface and bound water in drug substances by near infrared spectroscopy. J Pharm Sci 92:1058-1065. (Pubitemid 36523452)
53. Hogan SE, Buckton G. 2001. Water sorption/desorption - Near IR and calorimetric study of crystalline and amorphous raffinose. Int J Pharm 227:57-69. (Pubitemid 32868760)
54. Higgins JP, Arrivo SM, Reed RA. 2003. Approach to the determination of hydrate form conversions of drug compounds and solid dosage forms by near-infrared spectroscopy. J Pharm Sci 92:2303-2316.
55. Simpson MB. 2005. Near-infrared spectroscopy for process analytical chemistry: Theory, technology and implementation. In: Bakeev KA, editor. Process analytical technology. 1st edition. Oxford, UK: Blackwell Publishing Ltd. pp. 39-90.
56. McCreery RL. 2000. Raman spectroscopy for chemical analysis. New York: John Wiley & Sons, Inc.
57. Johansson J, Pettersson S, Folestad S. 2005. Characterization of different laser irradiation methods for quantitative Raman tablet assessment. J Pharm Biomed Anal 39:510-516. (Pubitemid 41196056)
58. De Beer TRM, Vergote GJ, Baeyens WRG, Remon JP, Vervaet C, Verpoort F. 2004. Development and validation of a direct, non-destructive quantitative method for medroxyprogesterone acetate in a pharmaceutical suspension using FT-Raman spectroscopy. Eur J Pharm Sci 23:355-362. (Pubitemid 39573386)
59. De Spiegeleer B, Seghers D, Wieme R, Schaubroeck J, Verpoort F, Slegers G, Van Vooren L. 2005. Determination of the relative amounts of three crystal forms of a benzimidazole drug in complex finished formulations by FT-Raman spectroscopy. J Pharm Biomed Anal 39:275-280. (Pubitemid 41112146)
60. Aaltonen J, Kogermann K, Strachan CJ, Rantanen J. 2007. In-line monitoring of solid-state transitions during fluidisation. Chem Eng Sci 62:408-415. (Pubitemid 44750896)
61. Niemczyk TM, Delgado-Lopez MM, Allen FS. 1998. Quantitative determination of bucindolol concentration in intact gel capsules using Raman spectroscopy. Anal Chem 70:2762-2765. (Pubitemid 28353995)
62. Schmuttenmaer CA. 2004. Exploring dynamics in the far-infrared with terahertz spectroscopy. Chem Rev 104:1759-1779.
63. Taday PF, Newnham DA. 2004. Technological advances in terahertz pulsed systems bring far-infrared into the spotlight. Spectrosc Eur 16:20-24.
64. Zeitler JA, Taday PF, Newnham DA, Pepper M, Gordon KC, Rades T. 2007. Terahertz pulsed spectroscopy and imaging in the pharmaceutical setting - a review. J Pharm Pharmacol 59:209-223. (Pubitemid 46203060)
65. Chantry GW. 1971. Submillimetre spectroscopy: A guide to the theoretical and experimental physics of the far infrared. London: Academic Press Ltd. p. 385.
66. Strachan CJ, Rades T, Newnham DA, Gordon KC, Pepper M, Taday PF. 2004. Using terahertz pulsed spectroscopy to study crystallinity of pharmaceutical materials. Chem Phys Lett 390:20-24.
67. Allis DG, Prokhorova DA, Korter TM. 2006. Solid-state modeling of the terahertz spectrum of the high explosive HMX. J Phys Chem A 110:1951-1959.
68. Day GM, Zeitler JA, Jones W, Rades T, Taday PF. 2006. Understanding the influence of polymorphism on phonon spectra: Lattice dynamics calculations and terahertz spectroscopy of carbamazepine. J Phys Chem B 110:447-456. (Pubitemid 43133567)
69. Zeitler JA, Newnham DA, Taday PF, Strachan CJ, Pepper M, Gordon KC, Rades T. 2005. Temperature dependent terahertz pulsed spectroscopy of carbamazepine. Thermochim Acta 436:71-77. (Pubitemid 41260402)
70. Zeitler JA, Newnham DA, Taday PF, Threlfall TL, Lancaster RW, Berg RW, Strachan CJ, Pepper M, Gordon KC, Rades T. 2006. Characterization of temperature-induced phase transitions in five polymorphic forms of sulfathiazole by terahertz pulsed spectroscopy and differential scanning calorimetry. J Pharm Sci 95:2486-2498. (Pubitemid 44726388)
71. Liu HB, Chen YQ, Zhang XC. 2007. Characterization of anhydrous and hydrated pharmaceutical materials with THz time-domain spectroscopy. J Pharm Sci 96:927-934.
72. Zeitler JA, Kogermann K, Rantanen J, Rades T, Taday PF, Pepper M, Aaltonen J, Strachan CJ. 2007. Drug hydrate systems and dehydration processes studied by terahertz pulsed spectroscopy. Int J Pharm 334:78-84. (Pubitemid 46400317)
73. Kogermann K, Zeitler JA, Rantanen J, Rades T, Taday PF, Pepper M, Heinämäki J, Strachan CJ. 2007. Investigating dehydration from compacts using terahertz pulsed, Raman, and near-infrared spectroscopy. Appl Spectrosc 61:1265-1274. (Pubitemid 351189512)
74. Taday PF, Bradley IV, Arnone DD, Pepper M. 2003. Using terahertz pulse spectroscopy to study the crystalline structure of a drug: A case study of the polymorphs of ranitidine hydrochloride. J Pharm Sci 92:831-838. (Pubitemid 36396998)
75. Wold S, Antti H, Lindgren F, Öhman J. 1998. Orthogonal signal correction of near-infrared spectra. Chemom Intell Lab Syst 44:175-185. (Pubitemid 29016095)
76. Andersson CA. 1999. Direct orthogonalization. Chemom Intell Lab Syst 47:51-63.
77. Fearn T. 2000. On orthogonal signal correction. Chemom Intell Lab Syst 50:47-52.
78. Feudale RN, Tan HW, Brown SD. 2002. Piecewise orthogonal signal correction. Chemom Intell Lab Syst 63:129-138.
79. Höskuldsson A. 2001. Variable and subset selection in PLS regression. Chemom Intell Lab Syst 55:23-38. (Pubitemid 32143780)
80. Trygg J, Wold S. 2002. Orthogonal projections to latent structures (O-PLS). J Chemom 16:119-128.
81. Trygg J. 2002. O2-PLS for qualitative and quantitative analysis in multivariate calibration. J Chemom 16:283-293.
82. Westerhuis JA, de Jong S, Smilde AK. 2001. Direct orthogonal signal correction. Chemom Intell Lab Syst 56:13-25.
83. Kogermann K, Aaltonen J, Strachan CJ, Pollanen K, Heinamaki J, Yliruusi J, Rantanen J. 2008. Establishing quantitative in-line analysis of multiple solid-state transformations during dehydration. J Pharm Sci 97:4983-4999.
84. Wold S, Martens H, Wold H. 1983. The multivariate calibration-problem in chemistry solved by the PLS method. Lect Notes Math 973:286-293.
85. Kourti T, MacGregor JF. 1995. Process analysis, monitoring and diagnosis, using multivariate projection methods. Chemom Intell Lab Syst 28:3-21.
86. Höskuldsson A. 1996. Prediction methods in science and technology. Warsaw: Colourscan.
87. Martens H, Naes T. 1993. Multivariate calibration. 1st edition. Chichester: John Wiley & Sons.
88. Davey R, Garside J. 2000. From molecules to crystallizers. An introduction to crystallization. Oxford: Oxford University Press.
89. Starbuck C, Spartalis A, Wai L, Wang J, Fernandez P, Lindemann CM, Zhou GX, Ge ZH. 2002. Process optimization of a complex pharmaceutical polymorphic system via in situ Raman spectroscopy. Cryst Growth Des 2:515-522.
90. Kobayashi R, Fujimaki Y, Ukita T, Hiyama Y. 2006. Monitoring of solvent-mediated polymorphic transitions using in situ analysis tools. Org Process Res Dev 10:1219-1226. (Pubitemid 44915964)
91. Févotte G. 2002. New perspectives for the on-line monitoring of pharmaceutical crystallization processes using in situ infrared spectroscopy. Int J Pharm 241:263-278. (Pubitemid 34718028)
92. Pöllänen K, Häkkinen A, Reinikainen SP, Rantanen J, Karjalainen M, Louhi-Kultanen M, Nyström L. 2005. IR spectroscopy together with multivariate data analysis as a process analytical tool for in-line monitoring of crystallization process and solid-state analysis of crystalline product. J Pharm Biomed Anal 38:275-284. (Pubitemid 40740225)
93. Févotte G, Calas J, Puel F, Hoff C. 2004. Applications of NIR spectroscopy to monitoring and analyzing the solid state during industrial crystallization processes. Int J Pharm 273:159-169. (Pubitemid 38317049)
94. Norris T, Aldridge PK, Sekulic SS. 1997. Determination of end-points for polymorph conversions of crystalline organic compounds using on-line near-infrared spectroscopy. Analyst 122:549-552. (Pubitemid 27277822)
95. Otsuka M, Kaneniwa N. 1984. Effects of grinding on the physicochemical properties of cephalexin powder. Chem Pharm Bull 32:1071-1079. (Pubitemid 14131833)
96. Otsuka M, Matsuda Y. 1993. Effect of environmental humidity on the transformation pathway of nitrofurantoin modifications during grinding and the physicochemical properties of ground products. J Pharm Pharmacol 45:406-413. (Pubitemid 23162437)
97. Ito S, Kobayashi Y, Nishimura M, Matsumoto K, Itai S, Yamamoto K. 1996. Effect of pulverization on dehydration behavior of crystals of GK-128, a serotonin(3) receptor antagonist. J Pharm Sci 85:1117-1122. (Pubitemid 26338929)
98. Puttipipatkhachorn S, Yonemochi E, Oguchi T, Yamamoto K, Nakai Y. 1990. Effect of grinding on dehydration of crystal water of theophylline. Chem Pharm Bull 38:2233-2236. (Pubitemid 20338187)
99. Savolainen M, Jouppila K, Pajamo O, Christiansen L, Strachan C, Karjalainen M, Rantanen J. 2007. Determination of amorphous content in the pharmaceutical process environment. J Pharm Pharmacol 59:161-170. (Pubitemid 46203055)
100. Dugue J, Ceolin R, Rouland JC, Lepage F. 1991. Polymorphism of carbamazepine - Solid-state studies on carbamazepine dihydrate. Pharmaceutica Acta Helvetiae 66:307-310.
101. Otsuka M, Ofusa T, Matsuda Y. 1999. Effect of environmental humidity on the transformation pathway of carbamazepine polymorphic modifications during grinding. Colloids Surf B 13:263-273.
102. Kaneniwa N, Otsuka M. 1984. The interaction between water and cephalexin in the crystalline and noncrystalline states. Chem Pharm Bull 32:4551-4559. (Pubitemid 15177833)
103. Leung SS, Padden BE, Munson EJ, Grant DJW. 1998. Solid-state characterization of two polymorphs of aspartame hemihydrate. J Pharm Sci 87:501-507. (Pubitemid 28175813)
104. Arrivo SM, Han R, Thomas DL, Thurau G, Bowen WE, Timmermans JHMT, Reed RA. 2001. Spectroscopic in-line monitoring and process control of a particle size reduction unit operation. Abstr Papers Am Chem Soc 222:U108.
105. Van Tonder EC, De Villiers MM, Lotter AP, Caira MR, Liebenberg W. 1998. Correlation between hydrate formation and the physical instability of suspensions prepared with different niclosamide crystal forms. Pharm Ind 60:722-725. (Pubitemid 28421413)
106. Tian F, Saville DJ, Gordon KC, Strachan CJ, Zeitler JA, Sandler N, Rades T. 2007. The influence of various excipients on the conversion kinetics of carbamazepine polymorphs in aqueous suspension. J Pharm Pharmacol 59:193-201. (Pubitemid 46203058)
107. Park SC, Kim M, Noh J, Chung H, Woo Y, Lee J, Kemper MS. 2007. Reliable and fast quantitative analysis of active ingredient in pharmaceutical suspension using Raman spectroscopy. Anal Chim Acta 593:46-53. (Pubitemid 46776630)
108. De Beer TRM, Baeyens WG, Vander Heyden Y, Remon JP, Vervaet C, Verpoort F. 2007. Influence of particle size on the quantitative determination of salicylic acid in a pharmaceutical ointment using FT-Raman spectroscopy. Eur J Pharm Sci 30:229-235. (Pubitemid 46282439)
109. Tian F, Zeitler JA, Strachan CJ, Saville DJ, Gordon KC, Rades T. 2006. Characterizing the conversion kinetics of carbamazepine polymorphs to the dihydrate in aqueous suspension using Raman spectroscopy. J Pharm Biomed Anal 40:271-280. (Pubitemid 43143330)
110. Jørgensen A, Rantanen J, Karjalainen M, Khriachtchev L, Rasanen E, Yliruusi J. 2002. Hydrate formation during wet granulation studied by spectroscopic methods and multivariate analysis. Pharm Res 19:1285-1291.
111. Sandler N, Rantanen J, Heinämäki J, Römer M, Marvola M, Yliruusi J. 2005. Pellet manufacturing by extrusion-spheronization using process analytical technology. Aaps Pharmscitech 6:E174-E183. (Pubitemid 41631755)
112. Mirza S, Miroshnyk I, Rantanen J, Aaltonen I, Harjula P, Kiljunen E, Heinämaki J, Yliruusi J. 2007. Solid-state properties and relationship between anhydrate and monohydrate of Baclofen. J Pharm Sci 96:2399-2408. (Pubitemid 47477895)
113. Wikström H, Marsac PJ, Taylor LS. 2005. In-line monitoring of hydrate formation during wet granulation using Raman spectroscopy. J Pharm Sci 94:209-219. (Pubitemid 40116384)
114. Wikström H, Rantanen J, Gift AD, Taylor LS. 2008. Toward an understanding of the factors influencing anhydrate-to-hydrate transformation kinetics in aqueous environments. Cryst Growth Des 8:2684-2693.
115. Strachan CJ, Howell SL, Aaltonen J, Heinz A, Kogermann K, Rantanen J. 2007. Insight into the metastable form of theophylline monohydrate using vibrational spectroscopy, computational chemistry and multivariate analysis. Eur J Pharm Sci 32:S8.
116. Räsänen E, Rantanen J, Mannermaa JP, Yliruusi J, Vuorela H. 2003. Dehydration studies using a novel multichamber microscale fluid bed dryer with in-line near-infrared measurement. J Pharm Sci 92:2074-2081. (Pubitemid 37175637)
117. Airaksinen S, Karjalainen M, Rasanen E, Rantanen J, Yliruusi J. 2004. Comparison of the effects of two drying methods on polymorphism of theophylline. Int J Pharm 276:129-141. (Pubitemid 38542994)
118. Liu HB, Zhang XC. 2006. Dehydration kinetics of D-glucose monohydrate studied using THz time-domain spectroscopy. Chem Phys Lett 429:229-233.
119. Hausman DS, Cambron RT, Sakr A. 2005. Application of on-line Raman spectroscopy for characterizing relationships between drug hydration state and tablet physical stability. Int J Pharm 299:19-33. (Pubitemid 40962402)
120. Masters K. 2002. Spray drying in practice. 1st edition. Charlottenlund: SprayDryConsult International ApS.
121. Ameri M, Maa YF. 2006. Spray drying of biopharmaceuticals: Stability and process considerations. Drying Technol 24:763-768. (Pubitemid 43820928)
122. Yu L. 2001. Amorphous pharmaceutical solids: Preparation, characterization and stabilization. Adv Drug Deliv Rev 48:27-42. (Pubitemid 32454482)
123. Harjunen PI, Lehto VP, Valisaari J, Lankinen T, Paronen P, Jarvinen K. 2002. Effects of ethanol to water ratio in feed solution on the crystallinity of spray-dried lactose. Drug Dev Ind Pharm 28:949-955.
124. Gombas A, Antal I, Szabo-Revesz P, Marton S, Eros I. 2003. Quantitative determination of crystallinity of alpha-lactose monohydrate by near infrared spectroscopy (NIRS). Int J Pharm 256:25-32. (Pubitemid 36416620)
125. Nørgaard L, Hahn MT, Knudsen LB, Farhatc IA, Engelsen SB. 2005. Multivariate near-infrared and Raman spectroscopic quantifications of the crystallinity of lactose in whey permeate powder. Int Dairy J 15:1261-1270. (Pubitemid 41219221)
126. Pikal MJ. 2007. Freeze drying. In: Swarbrick J, editor. Encyclopedia of pharmaceutical technology. 3rd edition. New York: Informa Healthcare USA, Inc. pp. 1807-1833.
127. Cao WJ, Mao C, Chen W, Lin H, Krishnan S, Cauchon N. 2006. Differentiation and quantitative determination of surface and hydrate water in lyophilized mannitol using NIR spectroscopy. J Pharm Sci 95:2077-2086. (Pubitemid 44433035)
128. Brülls M, Folestad S, Sparen A, Rasmuson A. 2003. In-situ near-infrared spectroscopy monitoring of the lyophilization process. Pharm Res 20:494-499. (Pubitemid 36288382)
129. De Beer TRM, Allesø M, Goethals F, Coppens A, Vander Heyden Y, Lopez De Diego H, Rantanen J, Verpoort F, Vervaet C, Remon JP, Baeyens WRG. 2007. Implementation of a process analytical technology system in a freeze-drying process using Raman spectroscopy for in-line process monitoring. Anal Chem 79:7992-8003. (Pubitemid 350059993)
130. Romero-Torres S, Wikström H, Grant ER, Taylor LS. 2007. Monitoring of mannitol phase behavior during freeze-drying using non-invasive Raman spectroscopy. PDA J Pharm Sci Technol 61:131-145. (Pubitemid 46651445)
131. Suihko E, Lehto VP, Ketolainen J, Laine E, Paronen P. 2001. Dynamic solid-state and tableting properties of four theophylline forms. Int J Pharm 217:225-236. (Pubitemid 32268648)
132. Ketolainen J, Poso A, Viitasaari V, Gynther J, Pirttimaki J, Laine E, Paronen P. 1995. Changes in solid-state structure of cyclophosphamide monohydrate induced by mechanical treatment and storage. Pharm Res 12:299-304.
133. Buxton PC, Lynch IR, Roe JM. 1988. Solid-state forms of paroxetine hydrochloride. Int J Pharm 42:135-143.
134. Airaksinen S, Luukkonen P, Jorgensen A, Karjalainen M, Rantanen J, Yliruusi J. 2003. Effects of excipients on hydrate formation in wet masses containing theophylline. J Pharm Sci 92:516-528. (Pubitemid 36258966)
135. Jørgensen AC, Airaksinen S, Karjalainen M, Luukkonen P, Rantanen J, Yliruusi J. 2004. Role of excipients in hydrate formation kinetics of theophylline in wet masses studied by near-infrared spectroscopy. Eur J Pharm Sci 23:99-104. (Pubitemid 39486002)
136. Airaksinen S, Karjalainen M, Kivikero N, Westermarck S, Shevchenko A, Rantanen J, Yliruusi J. 2005. Excipient selection can significantly affect solid-state phase transformation in formulation during wet granulation. Aaps Pharmscitech 6:E311-E322. (Pubitemid 41631741)
137. Wikström H, Carroll WJ, Taylor LS. 2008. Manipulating theophylline monohydrate formation during high-shear wet granulation through improved understanding of the role of pharmaceutical excipients. Pharm Res 25:923-935. (Pubitemid 351661841)
138. Tantry JS, Tank J, Suryanarayanan R. 2007. Processing-induced phase transitions of theophylline - Implications on the dissolution of theophylline tablets. J Pharm Sci 96:1434-1444. (Pubitemid 46797500)
139. Salameh AK, Taylor LS. 2006. Physical stability of crystal hydrates and their anhydrates in the presence of excipients. J Pharm Sci 95:446-461.
140. Zietsman S, Kilian G, Worthington M, Stubbs C. 2007. Formulation development and stability studies of aqueous metronidazole benzoate suspensions containing various suspending agents. Drug Dev Ind Pharm 33:191-197. (Pubitemid 46568304)
141. Betigeri S, Thakur A, Shukla R, Raghavan K. 2008. Effect of polymer additives on the transformation of BMS-566394 anhydrate to the dihydrate form. Pharm Res 25:1043-1051.
142. Gift AD, Luner PE, Luedeman L, Taylor LS. 2008. Influence of polymeric excipients on crystal hydrate formation kinetics in aqueous slurries. J Pharm Sci 97:5198-5211.
143. Schmidt AG, Wartewig S, Picker KM. 2003. Potential of carrageenans to protect drugs from polymorphic transformation. Eur J Pharm Biopharm 56:101-110. (Pubitemid 36802053)
144. Schmidt AG, Wartewig S, Picker KM. 2004. Polyethylene oxides: Protection potential against polymorphic transitions of drugs? J Raman Spectrosc 35:360-367.
145. Cogdill RP, Drennen JK. 2006. Near-infrared spectroscopy. In: Brittain HG, editor. Spectroscopy of pharmaceutical solids. 1st edition. New York: Taylor & Francis Group. pp. 313-412.
146. Coates JP. 2005. Infrared spectroscopy for process analytical applications. In: Bakeev KA, editor. Process analytical technology. Oxford: Blackwell Publishing Ltd. pp. 91-132.
147. Kemeny GJ. 2001. Process analysis. In: Burns DA, Ciurczak EW, editors. Handbook of near-infrared analysis. 2nd edition. New York: Marcel Dekker, Inc. pp. 729-782.
148. Jestel NL. 2005. Process Raman spectroscopy. In: Bakeev KA, editor. Process analytical technology. 1st edition. Oxford: Blackwell Publishing Ltd. pp. 133-169.
149. Caillet A, Puel F, Fevotte G. 2008. Quantitative in situ monitoring of citric acid phase transition in water using Raman spectroscopy. Chem Eng Process 47:377-382.
150. Burgbacher J, Wiss J. 2008. Industrial applications of online monitoring of drying processes of drug substances using NIR. Org Process Res Dev 12:235-242.
151. Römer M, Heinämäki J, Miroshnyk I, Sandler N, Rantanen J, Yliruusi J. 2007. Phase transformations of erythromycin A dihydrate during pelletisation and drying. Eur J Pharm Biopharm 67:246-252. (Pubitemid 46991315)
152. Nolasco MM, Amado AM, Ribeiro-Claro PJA. 2006. Computationally-assisted approach to the vibrational spectra of molecular crystals: Study of hydrogen-bonding and pseudo-polymorphism. Chem Phys Chem 7:2150-2161.